VIRTUAL SYMPOSIUMCurrent and Future Perspectives for Bispecific Antibodies in Multiple Myeloma: Learnings from 2023
An ACCME Accredited Educational Program
March 11, 2024
8:00–9:30 EST
LIVE VIRTUAL SYMPOSIUM
Current and Future Perspectives for Bispecific Antibodies in Multiple Myeloma: Learnings from 2023
An opportunity for participants to interact with a world-renowned faculty and hear their expert recommendations on current and future perspectives for bispecific antibodies in multiple myeloma.
Multiple myeloma (MM) is the second most common hematologic malignancy. Following the approval of a number of agents active against MM, there are numerous possible treatment combinations that can be used in first-line and relapsed settings. Moreover, numerous newer therapies, such as bispecific antibodies, are in development and likely to hugely impact MM; therefore, understanding such developments and how new agents can be integrated into the treatment landscape is a key need for healthcare professionals. Furthermore, due to improved survival, the prevalence of relapsed disease is increasing, and the management of treatment side effects is more critical with longer-term treatment.
This 90-minute Multiple Myeloma Hub Symposium, chaired by Sagar Lonial, will provide an opportunity for participants to interact with a world-renowned faculty and hear their current and future perspectives for bispecific antibodies in multiple myeloma.
Agenda
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Scientific Education Support (SES). ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Guidelines require that learners in CME activities be made aware of all relevant financial relationships affecting the presentation of the faculty member. ACHL ensures that all faculty and staff involved in the planning, development, and implementation of ACHL activities disclose financial relationships held within 24 months and that relevant financial relationships are mitigated before a CME activity occurs. Complete information will be provided to learners prior to the start of the educational activity.
Learning objectives
Upon completion of this activity, participants should be able to:
- Describe novel therapeutic targets in MM and explain the mechanisms of action for new agents in MM
- State the rationale for selecting treatments in relapsed/refractory disease based on disease- and patient-related factors
- Recall key safety and efficacy data for new agents and relate this to treatment selection
- Employ patient-specific considerations in the development of personalized treatment plans
Our speakers
Meet our panel of experts
Sagar Lonial
Winship Cancer Institute of Emory University
Atlanta, US
Naresh Bumma
Ohio State University
Columbus, US
Amrita Krishnan
City of Hope
Duarte, US
Sergio Giralt
Memorial Sloan Kettering Cancer Center
New York, US
About the Multiple Myeloma Hub
The Multiple Myeloma Hub is an open-access, online resource dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The Multiple Myeloma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
About ACHL
ACHL's mission is to design, develop, and implement quality continuing education activities for medical and pharmacy professionals across diverse practice settings that will have a positive influence on the way healthcare is practiced and improve patient outcomes.
ACHL's vision is to improve health outcomes through collaborative, impactful education.